Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT04509596
Title DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Dizal Pharmaceuticals
Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
UCLA Hematology/Oncology Parkside Santa Monica California 90404 United States Details
Zhejiang Cancer Hospital Hangzhou China Details
Cancer Hospital, Fudan University Shanghai China Details
*Shaded cells indicate that there was no data available from for the field